Literature DB >> 2783598

Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets.

J Jääskeläinen1, P Kalliomäki, A Paetau, T Timonen.   

Abstract

The anti-tumor mechanisms of local LAK cell therapy are difficult to study in vivo. We describe a method to study in vitro the action of LAK cells against three-dimensional tumor tissue. Spherical cell aggregates (spheroids) grown from human glioma cell lines H-2 and U-251 were labeled with 51Cr and then incubated for up to 24 h with LAK cells. After the incubation, most spheroids were still macroscopically identifiable, and the measured reduction of volume did not correlate to the extent of damage. LAK cells infiltrated into spheroid tissue slowly as a frontier which explains why the specific 51Cr release was clearly slower from spheroids than corresponding single cell suspensions. The infiltrated area was at 1 to 2 h very thin but by 8 to 12 h consisted already of several cell layers. Most H-2 spheroids became totally infiltrated by 16 to 24 h whereas in U-251 spheroids the infiltration usually remained peripheral. In accordance with the different extent of infiltration, H-2 spheroids were clearly more sensitive to LAK cells than U-251 spheroids: at E/T ratio 10:1 the mean specific 51Cr release by 24 h was 63 and 36%, respectively. A single exposure to LAK cells released 51Cr from H-2 spheroids approximately 12 h but over 24 h from U-251 spheroids. The spheroid model can be used to study the infiltrative capacity and cytotoxicity of LAK cells against three-dimensional tumor tissue, and the method may help to find an optimal mode of local LAK cell therapy, i.e., proper combination of lymphokines and LAK cells, and proper timing of their administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783598

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Complement-mediated killing of microtumors in vitro.

Authors:  J Hakulinen; S Meri
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

2.  Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.

Authors:  A Mäenpää; S Junnikkala; J Hakulinen; T Timonen; S Meri
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

3.  A multicellular tumor spheroid model of cellular immunity against head and neck cancer.

Authors:  P G Sacks; D L Taylor; T Racz; T Vasey; V Oke; S P Schantz
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 4.  New aspects of immunotherapy of leptomeningeal metastasis.

Authors:  U Herrlinger; M Weller; M Schabet
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

5.  Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.

Authors:  A Boiardi; A Silvani; P A Ruffini; L Rivoltini; G Parmiani; G Broggi; A Salmaggi
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

6.  Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

Authors:  P A Ruffini; L Rivoltini; A Silvani; A Boiardi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

7.  Assessment of the number of local cytotoxic T lymphocytes required for degradation of micrometer-size tumor spheroids.

Authors:  K Kawai; H Hayashi; Y Ozaki; K Saijo; S Q Liu; H Akaza; T Ohno
Journal:  Cytotechnology       Date:  2001-09       Impact factor: 2.058

8.  Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.

Authors:  L Bjørge; S Junnikkala; E K Kristoffersen; J Hakulinen; R Matre; S Meri
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.

Authors:  S Junnikkala; J Hakulinen; H Jarva; T Manuelian; L Bjørge; R Bützow; P F Zipfel; S Meri
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.